Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tislelizumab + anlotinib + nab-paclitaxel neoadjuvant therapy in resectable stage III NSCLC
ChiCTR2500114484Phase 2Not yet recruiting
- Sponsor
- Qilu Hospital of Shandong University
- Start
- Dec 2025
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tislelizumab, anlotinib and paclitaxel in non-small cell lung cancer (NSCLC), sponsored by Qilu Hospital of Shandong University. Primary endpoint: pathological complete response (pCR) rate. Planned start Dec 2025; status: not yet recruiting.
02
Drugs
tislelizumabanlotinibpaclitaxel
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2500114484.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500114484.